Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Nakamura

Showing results (611-620 of 709) with videos related to

Pageof 71
Sort By:
World Journal of Gastroenterology|December 11, 2014
Endoscopic papillary large balloon dilation for removal of bile duct stonesYuji Sakai, Toshio Tsuyuguchi, Yoshiaki Kawaguchi, et al.
Cancer Medicine|November 22, 2020
Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trialAkira Ooki, Satoshi Morita, Akihito Tsuji, et al.
The Journal of Invasive Cardiology|September 8, 2012
Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doingShigeru Saito, Shigeru Nakamura, Kenshi Fujii, et al.
Angiology|February 6, 2015
Postprocedural Skin Perfusion Pressure Correlates With Clinical Outcomes 1 Year After Endovascular Therapy for Patients With Critical Limb IschemiaShin Okamoto, Osamu Iida, Masato Nakamura, et al.
Hepato-Gastroenterology|April 11, 2007
Overexpression of MT3-MMP in hepatocellular carcinoma correlates with capsular invasionIsao Arai, Hiroaki Nagano, Motoi Kondo, et al.
Targeted Oncology|April 15, 2023
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)Ryohei Kawabata, Naoki Izawa, Takahisa Suzuki, et al.
British Journal of Cancer|September 1, 2020
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08Toshiki Masuishi, Akihito Tsuji, Masahito Kotaka, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2021
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trialTadamichi Denda, Atsuo Takashima, Makio Gamoh, et al.
International Journal of Clinical Oncology|May 31, 2022
Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study)Shun Ishiyama, Takeshi Yamada, Masato Nakamura, et al.
JAMA Oncology|September 13, 2019
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical TrialTakayuki Yoshino, Takeharu Yamanaka, Eiji Oki, et al.
Pageof 71

Showing results (611-620 of 709) with videos related to

Sort By:
Pageof 71
World Journal of Gastroenterology|December 11, 2014
Endoscopic papillary large balloon dilation for removal of bile duct stonesYuji Sakai, Toshio Tsuyuguchi, Yoshiaki Kawaguchi, et al.
Cancer Medicine|November 22, 2020
Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trialAkira Ooki, Satoshi Morita, Akihito Tsuji, et al.
The Journal of Invasive Cardiology|September 8, 2012
Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doingShigeru Saito, Shigeru Nakamura, Kenshi Fujii, et al.
Angiology|February 6, 2015
Postprocedural Skin Perfusion Pressure Correlates With Clinical Outcomes 1 Year After Endovascular Therapy for Patients With Critical Limb IschemiaShin Okamoto, Osamu Iida, Masato Nakamura, et al.
Hepato-Gastroenterology|April 11, 2007
Overexpression of MT3-MMP in hepatocellular carcinoma correlates with capsular invasionIsao Arai, Hiroaki Nagano, Motoi Kondo, et al.
Targeted Oncology|April 15, 2023
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)Ryohei Kawabata, Naoki Izawa, Takahisa Suzuki, et al.
British Journal of Cancer|September 1, 2020
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08Toshiki Masuishi, Akihito Tsuji, Masahito Kotaka, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2021
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trialTadamichi Denda, Atsuo Takashima, Makio Gamoh, et al.
International Journal of Clinical Oncology|May 31, 2022
Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study)Shun Ishiyama, Takeshi Yamada, Masato Nakamura, et al.
JAMA Oncology|September 13, 2019
Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical TrialTakayuki Yoshino, Takeharu Yamanaka, Eiji Oki, et al.
Pageof 71